About 200 reports

  • GLOBAL PREMATURE EJACULATION TREATMENT MARKET BY SSRIS 2016-2021 ($ MILLIONS)
  • SSRIS

These drugs find applications in the treatment of anxiety, depression, and personality disorders.

  • Pharmaceutical
  • Therapy
  • World
  • Forecast
  • Eli Lilly & Co.
  • Clinical Trial profile. 168 Trial Title
  • 5. All the trials included are unique trials.

Psychosis Global Clinical Trials Review, H1, 2018 Summary GlobalData’s clinical trial report, “Psychosis Global Clinical Trials Review, H1, 2018" provides an overview of Psychosis clinical trials scenario.This report provides top line data relating to the clinical trials on Psychosis. Report...

  • Antipsychotic
  • Cardiovascular Drug
  • Clinical Trial
  • Neurology
  • Psychotic Disorder
  • UNIPOLAR DEPRESSION

About Antipsychotic Drugs Antipsychotic drugs are also called as major tranquilizers or neuroleptics. These drugs are primarily used for the treatment of psychiatric disorders such as schizophrenia, hallucinations, delusions, bipolar disorder, and others. The antipsychotic drugs market is expected to grow due to the rising number...

  • Antipsychotic
  • Psychotic Disorder
  • AstraZeneca PLC
  • Eli Lilly & Co.
  • GlaxoSmithKline plc
  • Description

Chapter ## provides an introduction to the report.

  • Mental Health
  • Pathology
  • World
  • Demand
  • NEURODEGENERATIVE DISORDERS THERAPEUTICS MARKET, COMORBIDITIES ASSOCIATED WITH

Global Neurodegenerative Drugs Market to 2022 - Growth Driven by an Aging Population, the Approval of Novel Immunomodulators and Neuromodulators, and Strong Uptake of Marketed Anti-Inflammatory Treatments Summary Neurodegenerative disorders are a cluster of conditions that affect the central nervous system. They include...

  • Clinical Trial
  • Dementia
  • Therapy
  • World
  • Biogen Idec Inc.
  • LEO PHARMA AND LEO PHARMA A/S ENTER INTO AGREEMENT WITH KYOWA HAKKO KIRIN
  • LEO PHARMA ENTERS INTO DISTRIBUTION AND CO-PROMOTION AGREEMENT WITH KYOWA HAKKO KIRIN

Its development pipeline consists of various protein, antibody and small molecule formulations for the treatment of neutropenia, anemia, chronic idiopathic thrombocytopenic purpura, hypertension, angina pectoris, allergic rhinitis, epilepsy, behavioral or personality disorders and

  • Dermatological Condition
  • Healthcare
  • Pathology
  • Pharmaceutical
  • LEO Pharma A/S
  • PIPELINE BY TAKEDA PHARMACEUTICAL CO LTD, H1 2018
  • KYOWA HAKKO KIRIN CO LTD

Its development pipeline consists of various protein, antibody and small molecule formulations for the treatment of neutropenia, anemia, chronic idiopathic thrombocytopenic purpura, hypertension, angina pectoris, allergic rhinitis, epilepsy, behavioral or personality disorders and

  • Digestive System Disorder
  • Hormone
  • Therapy
  • World
  • Gilead Sciences, Inc.
  • 4.5 Personality Disorders
  • 20 Personality disorders market, 2014 - 2025 (USD Billion)

The global behavioral rehabilitation market is expected to reach USD 313.9 billion by 2025, according to a new report by Grand View Research, Inc. Behavioral rehabilitation market is anticipated to experience growth during the forecast period due to presence of favorable government initiatives, rising number of service providers, and growing...

  • Healthcare
  • United States
  • Forecast
  • Products and services segmentation (2017)
  • INDUSTRY DEFINITION

Road to recovery: Demand will increase as mental health becomes less socially stigmatized Abstract Mental Health & Substance Abuse Centres in Canada Over the five years to 2017, the rising awareness and acceptance of mental health and substance abuse illnesses have contributed to steady...

  • Addiction Disorder
  • Mental Health
  • Pathology
  • Canada
  • Demand
  • PIPELINE BY TAKEDA PHARMACEUTICAL CO LTD, H2 2017
  • KYOWA HAKKO KIRIN CO LTD

Its development pipeline consists of various protein, antibody and small molecule formulations for the treatment of neutropenia, anemia, chronic idiopathic thrombocytopenic purpura, hypertension, angina pectoris, allergic rhinitis, epilepsy, behavioral or personality disorders and

  • Digestive System Disorder
  • Therapy
  • World
  • Product Initiative
  • Gilead Sciences, Inc.
  • KYOWA HAKKO KIRIN ENTERS INTO LICENSING AGREEMENT WITH SANDOZ
  • KYOWA HAKKO KIRIN ENTERS INTO LICENSING AGREEMENT WITH SBI BIOTECH

Article ##.

  • Asthma
  • Healthcare
  • Pharmaceutical
  • Therapy
  • Kyowa Hakko Kirin Co., Ltd.
  • PIPELINE BY INTERNA TECHNOLOGIES BV, H1 2018
  • PIPELINE BY KYOWA HAKKO KIRIN CO LTD, H1 2018

Its development pipeline consists of various protein, antibody and small molecule formulations for the treatment of neutropenia, anemia, chronic idiopathic thrombocytopenic purpura, hypertension, angina pectoris, allergic rhinitis, epilepsy, behavioral or personality disorders and

  • Hospital
  • Oncology
  • Therapy
  • World
  • AstraZeneca PLC
  • PIPELINE BY KYOWA HAKKO KIRIN CO., LTD., H1 2016
  • FLX Bio Inc

Its development pipeline consists of various protein, antibody and small molecule formulations for the treatment of neutropenia, anemia, chronic idiopathic thrombocytopenic purpura, hypertension, angina pectoris, allergic rhinitis, epilepsy, behavioral or personality disorders and

  • Chemokine
  • Therapy
  • United States
  • World
  • Kyowa Hakko Kirin Co., Ltd.
  • PIPELINE BY HORIZON DISCOVERY GROUP PLC, H2 2017
  • PIPELINE BY KYOWA HAKKO KIRIN CO LTD, H2 2017

Its development pipeline consists of various protein, antibody and small molecule formulations for the treatment of neutropenia, anemia, chronic idiopathic thrombocytopenic purpura, hypertension, angina pectoris, allergic rhinitis, epilepsy, behavioral or personality disorders and

  • Hospital
  • Oncology
  • Research And Development
  • Therapy
  • AstraZeneca PLC
  • KYOWA HAKKO KIRIN CO LTD
  • JOHNSON & JOHNSON

Its development pipeline consists of various protein, antibody and small molecule formulations for the treatment of neutropenia, anemia, chronic idiopathic thrombocytopenic purpura, hypertension, angina pectoris, allergic rhinitis, epilepsy, behavioral or personality disorders and

  • Monoclonal Antibody
  • Therapy
  • United States
  • Product Initiative
  • Apexigen, Inc.
  • ASSET PURCHASE
  • ASSET PURCHASE

Rx PedPRM is to treat sleep disorders in children with autism spectrum disorders (ASD) and neurogenetic diseases.

  • Healthcare
  • Pharmaceutical
  • Therapy
  • M&A
  • Aspen Pharmacare Holdings Limited
  • ACTIVIOMICS ENTERS INTO RESEARCH AGREEMENT WITH KYOWA HAKKO
  • ACTIVIOMICS EXTENDS RESEARCH AGREEMENT WITH KYOWA HAKKO KIRIN

Its development pipeline consists of various protein, antibody and small molecule formulations for the treatment of neutropenia, anemia, chronic idiopathic thrombocytopenic purpura, hypertension, angina pectoris, allergic rhinitis, epilepsy, behavioral or personality disorders and

  • Healthcare
  • Influenza
  • Pharmaceutical
  • United Kingdom
  • hVIVO plc
  • KYOWA HAKKO KIRIN CO LTD
  • PIPELINE BY KYOWA HAKKO KIRIN CO LTD, H1 2018

Its development pipeline consists of various protein, antibody and small molecule formulations for the treatment of neutropenia, anemia, chronic idiopathic thrombocytopenic purpura, hypertension, angina pectoris, allergic rhinitis, epilepsy, behavioral or personality disorders and

  • Monoclonal Antibody
  • Therapy
  • United States
  • World
  • Product Initiative
  • SANFORD HEALTH ACQUIRES HEMATECH, DRUG DEVELOPMENT COMPANY
  • SANFORD HEALTH ACQUIRES HEMATECH, DRUG DEVELOPMENT COMPANY

Its development pipeline consists of various protein, antibody and small molecule formulations for the treatment of neutropenia, anemia, chronic idiopathic thrombocytopenic purpura, hypertension, angina pectoris, allergic rhinitis, epilepsy, behavioral or personality disorders and

  • Health Services
  • Healthcare
  • Pharmaceutical
  • United States
  • Caladrius Biosciences, Inc.
  • Kyowa Hakko Kirin - Overview
  • R&D EXPENSE

The Mid-Size Pharmaceutical Market: Market Assessment, Growth Forecasts and Strategic Consolidations for Key Players Summary The worldwide pharmaceutical market is projected to grow from approximately $1.1 trillion in 2016 to $1.5 trillion in 2021, representing a compound annual growth rate of 6.4%....

  • Pharmaceutical
  • Therapy
  • Alexion Pharmaceuticals, Inc.
  • Daiichi Sankyo Company
  • Eisai Co., Ltd.
  • KYOWA HAKKO KIRIN CO LTD
  • PIPELINE BY KYOWA HAKKO KIRIN CO LTD, H1 2018

It specializes in age-related disorders.

  • Pain Relief
  • Pharmaceutical
  • Research And Development
  • Therapy
  • Flex Pharma, Inc.
  • COMPANY OVERVIEW
  • SWOT Analysis

Kyowa Hakko Kirin Co Ltd (4151) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations.The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and...

  • Pharmaceutical
  • Japan
  • Company Financials
  • Kyowa Hakko Kirin Co., Ltd.
  • KYOWA HAKKO KIRIN CO LTD
  • PIPELINE BY MEDIMMUNE LLC, H2 2018

Its development pipeline consists of various protein, antibody and small molecule formulations for the treatment of neutropenia, anemia, chronic idiopathic thrombocytopenic purpura, hypertension, angina pectoris, allergic rhinitis, epilepsy, behavioral or personality disorders and

  • Monoclonal Antibody
  • Therapy
  • United States
  • Product Initiative
  • MedImmune, LLC
  • Clinical Trial profile. 500 Trial Title
  • 5. All the trials included are unique trials.

Cognitive Disorders Global Clinical Trials Review, H1, 2017 Summary GlobalData’s clinical trial report, “Cognitive Disorders Global Clinical Trials Review, H1, 2017" provides an overview of Cognitive Disorders clinical trials scenario. This report provides top line data relating to the clinical trials on Cognitive Disorders....

  • Clinical Trial
  • Dementia
  • Hospital
  • Neurology
  • Pharmaceutical
  • FUJIFILM FORMS JOINT VENTURE WITH KYOWA HAKKO KIRIN

Its development pipeline consists of various protein, antibody and small molecule formulations for the treatment of neutropenia, anemia, chronic idiopathic thrombocytopenic purpura, hypertension, angina pectoris, allergic rhinitis, epilepsy, behavioral or personality disorders and

  • Healthcare
  • Pharmaceutical
  • Therapy
  • Japan
  • FUJIFILM Holdings Corporation
  • DIGITAL THERAPEUTICS: LIST OF CLINICAL TRIALS (DETAILS ON TRIAL TITLE,
  • METABOLIC DISORDERS

ONE ##.

  • Application
  • Pharmaceutical
  • Therapy
  • World
  • Market Size
  • CLINICAL TRIAL PROFILE SNAPSHOTS

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Clinical Trial
  • Drug Discovery And Development
  • Hospital
  • Neurology
  • Therapy
  • INCYTE CORP
  • PIPELINE BY INCYTE CORP, H1 2018

Its development pipeline consists of various protein, antibody and small molecule formulations for the treatment of neutropenia, anemia, chronic idiopathic thrombocytopenic purpura, hypertension, angina pectoris, allergic rhinitis, epilepsy, behavioral or personality disorders and

  • Monoclonal Antibody
  • Oncology
  • Therapy
  • United States
  • Product Initiative
  • ORPEA SA: KEY FACTS
  • LEADING COMPANIES

Orpea' s psychiatric clinics facilities provide services for the patients with acute mental pathologies, such as mood disorders, anxiety disorders, addiction, overuse or burnout syndromes, chronic fatigue syndrome, fibromyalgia, sleep disorders, eating

  • Health Care Provider
  • Healthcare
  • Hospital
  • Western Europe
  • Market Size
  • Aevi Genomic Medicine Inc, Pharmaceuticals & Healthcare, Deal Details
  • Aevi Genomic Medicine Inc, Pharmaceuticals & Healthcare, Deal Details

Its development pipeline consists of various protein, antibody and small molecule formulations for the treatment of neutropenia, anemia, chronic idiopathic thrombocytopenic purpura, hypertension, angina pectoris, allergic rhinitis, epilepsy, behavioral or personality disorders and

  • Healthcare
  • Neurological Disorder
  • Therapy
  • United States
  • Medgenics, Inc.